Category-Personal Care
About Clobetasol 0.05% + Salicylic acid 6%
Clobetasol 0.05% + Salicylic Acid 6% Cream is a topical medicine used to treat inflammatory skin conditions associated with thick, scaly skin lesions, such as psoriasis and certain forms of eczema, as advised by a doctor.
It contains Clobetasol Propionate 0.05%, a potent corticosteroid that helps reduce redness, itching, swelling, and inflammation, whereas Salicylic Acid 6%, a keratolytic agent that softens and removes thickened, scaly skin by helping shed dead skin cells.
The cream is meant for external use only and should be applied as a thin layer to the affected area exactly as prescribed by your doctor. Prolonged or excessive use may increase the risk of side effects, especially when used over large areas of the body.
Regular use as directed helps control symptoms and improve skin comfort. The cream should be stored in a cool, dry place away from direct sunlight and heat.
Key Ingredients
Clobetasol Propionate 0.05% w/w, Salicylic Acid 6% w/w
Clobetasol 0.05% + Salicylic acid 6% Features
Special features of Clobetasol 0.05% + Salicylic acid 6% includes:
- Helps reduce skin inflammation and redness
- Relieves itching and irritation
- Helps remove thick scales and dead skin
- Softens hardened skin plaques
- Helps improve the appearance of scaly skin lesions
- Easy-to-apply topical cream formula
Clobetasol 0.05% + Salicylic acid 6% Benefits
- Helps manage psoriasis with thick scaling.
- Helps relieve itching, redness, and swelling.
- Helps reduce skin scaling and flaking.
- Softens and removes thickened skin plaques.
- Improves skin texture and appearance.
- Provides targeted treatment directly to affected areas.
- Helps reduce discomfort associated with inflammatory skin conditions.
- Supports better penetration and effectiveness of the medicine.
- Easy and convenient topical application.
- Helps improve overall skin comfort with regular use as prescribed.
Suitable For
Skin Type
Suitable for individuals with thick, scaly inflammatory skin conditions as advised by a doctor.
Who Can Use It
This cream is suitable for adults prescribed in this medicine for conditions such as psoriasis and certain steroid-responsive skin disorders associated with scaling. It should be used only under medical supervision.
How to Use Clobetasol 0.05% + Salicylic acid 6%
- Wash and dry the affected area gently before application.
- Apply a thin layer of the cream to the affected skin as directed by your doctor.
- Use clean hands while applying the cream.
- Do not apply more than the recommended amount.
- Avoid contact with eyes, mouth, nose, and other mucous membranes.
- Do not apply to cuts, open wounds, or infected skin unless advised by your doctor.
- Wash your hands after application, unless the hands are in the area being treated.
- Do not cover the treated area with airtight dressings unless instructed by your doctor.
- Use the prescribed duration only.
How to Store Clobetasol 0.05% + Salicylic acid 6%
- Store in a cool, dry place below room temperature.
- Keep away from direct sunlight and heat.
- Keep the tube tightly closed after use.
- Keep out of reach of children.
- Do not freeze the product.
Safety Info
- For external use only.
- Do not use if allergic to Clobetasol, Salicylic Acid, or any of the ingredients.
- Use only for the duration prescribed by your doctor.
- Avoid prolonged use over large areas of the body.
- Do not use on the face, groin, or underarms unless advised by your doctor.
- Avoid contact with eyes, lips, and mucous membranes.
- Mild burning, dryness, irritation, or peeling may occur at the application site.
- Stop using and consult a doctor if severe irritation, worsening of symptoms, or allergic reactions develop.
- Consult your doctor before using during pregnancy or breastfeeding.
- Keep regular follow-up appointments if long-term treatment is required.
FAQ’s
What does Clobetasol 0.05% + Salicylic Acid 6% do to the skin?
Clobetasol 0.05% + Salicylic Acid 6% cream reduces inflammation in the skin by blocking the release of inflammatory chemicals. This leads to less redness, swelling, and itching, making it effective for conditions like psoriasis and eczema
What are the side effects of Clobetasol 0.05% + Salicylic Acid 6% cream?
Common side effects of Clobetasol 0.05% + Salicylic Acid 6% cream include burning, stinging, itching, redness, dryness, or thinning of the skin. With long-term or excessive use, it may also cause stretch marks, acne-like eruptions, or systemic steroid effects such as adrenal gland problems.
Is Clobetasol 0.05% + Salicylic Acid 6% cream steroid?
Yes, Clobetasol 0.05% + Salicylic Acid 6% is a super‑potent topical corticosteroid (steroid medicine) used on the skin to reduce inflammation, redness, and itching in conditions like psoriasis and eczema.
References
- PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 5311051, Clobetasol; [cited 2026 Feb. 17]. Available from.
- Mayo Clinic. Clobetasol (topical application route) – Side effects & dosage. Mayo Clinic [Internet]. 2026 Feb 1 [cited 2026 Feb 17]. Available from.
- Cerner Multum. Clobetasol (cream, gel, ointment, lotion) – Uses, Side Effects & Warnings. Drugs.com [Internet]. 2023 Aug 11 [cited 2026 Feb 17]. Available from.
- Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S, Haq R, Mittal R, Mehta S, Mane A. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatol Ther. Available from.
Authors
Pranathi is a final year Pharm D student at Chalapathi Institute of Pharmaceutical Sciences. She loves learning and applying her knowledge in pharmacy and has a passion for writing, which allows her to express ideas clearly and creatively. She enjoys combining her technical skills with her love for writing and communication to make a meaningful impact. Currently she is working on a research paper about “Consanguineous marriages and its impact on children’s health” which will be published by the end of 2025.